State Street Corp Buys 10,401 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

State Street Corp increased its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 1.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 606,544 shares of the company’s stock after acquiring an additional 10,401 shares during the quarter. State Street Corp owned about 0.23% of Autolus Therapeutics worth $2,202,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of AUTL. HighVista Strategies LLC boosted its stake in Autolus Therapeutics by 2.7% during the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock valued at $1,935,000 after buying an additional 14,204 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of Autolus Therapeutics during the 3rd quarter valued at approximately $708,000. Bellevue Group AG boosted its position in shares of Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after acquiring an additional 9,000 shares during the last quarter. Capstone Investment Advisors LLC bought a new stake in Autolus Therapeutics in the third quarter worth $51,000. Finally, FMR LLC increased its position in Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after purchasing an additional 5,478,706 shares during the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Stock Performance

AUTL opened at $2.35 on Thursday. Autolus Therapeutics plc has a one year low of $2.07 and a one year high of $7.45. The stock has a market cap of $625.32 million, a price-to-earnings ratio of -1.94 and a beta of 1.98. The stock’s 50 day moving average price is $3.05 and its 200-day moving average price is $3.66.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the company posted ($0.26) earnings per share. As a group, analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on AUTL shares. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday, December 5th. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a report on Friday, November 15th. Finally, The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.